Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

FBRX

Forte Biosciences Inc

76.92

Aug 21 • 3:59 PM ET +0.03 (0.04%)

76.92

Aftermarket • 7:49 PM ET 0.00 (0.00%)

Healthcare Biotechnology USA Small NASD

Peers: KYMR BMRN CRNX RYTM INCY KRYS VKTX AXSM MDGL NBIX

| Held by: VTI IWM VXF IWO VTWO IWC ATFV FESM ITOT ARB

Scroll to Statements

Index	RUT
Market Cap	1.63B
Enterprise Value	1.43B
Income	-87.94M
Sales	0.00M
Book/sh	8.97
Cash/sh	9.35
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	19
IPO	Apr 13, 2017

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	8.57
P/C	8.23
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	10.01
Current Ratio	10.01
Debt/Eq	0.00
LT Debt/Eq	0.00
Option/Short	Yes / Yes

EPS (ttm)	-5.13
EPS next Y	-4.12
EPS next Q	-1.03
EPS this Y	17.39%
EPS next Y	-5.79%
EPS next 5Y	-
EPS past 3/5Y	38.19% 50.46%
Sales past 3/5Y	- -
EPS Y/Y TTM	35.82%
Sales Y/Y TTM	-
EPS Q/Q	-2.40%
Sales Q/Q	-
Earnings	May 11 BMO
EPS/Sales Surpr.	-6.90% -

Insider Own	19.16%
Insider Trans	0.00%
Inst Own	74.67%
Inst Trans	26.22%
ROA	-56.10%
ROE	-62.28%
ROIC	-47.85%
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	0.20%
SMA50	56.41%
SMA200	146.35%
Trades

Shs Outstand	20.48M
Shs Float	17.16M
Short Float	11.10%
Short Ratio	1.50
Short Interest	1.90M
52W High	77.20 -0.36%
52W Low	10.11 660.83%
Volatility	0.10% 0.69%
ATR (14)	1.55
RSI (14)	84.34
Beta	2.64
Rel Volume	1.59
Avg Volume	1.27M
Volume	2,012,128

Perf Week	0.12%
Perf Month	28.84%
Perf Quarter	249.64%
Perf Half Y	164.88%
Perf YTD	182.07%
Perf Year	592.35%
Perf 3Y	270.70%
Perf 5Y	-88.62%
Perf 10Y	-
Recom	3.00
Target Price	77.00
Prev Close	76.89
Price	76.92
Change %	0.04%

Date	Action	Analyst	Rating Change	Price Target Change
Jul-21-26	Initiated	Barclays	Overweight	$74
Nov-25-25	Initiated	Evercore ISI	Outperform	$65
Aug-18-25	Initiated	Guggenheim	Buy	$75
Jan-21-25	Initiated	TD Cowen	Buy
Apr-08-24	Upgrade	Ladenburg Thalmann	Neutral → Buy	$2.75
Sep-20-21	Upgrade	Chardan Capital Markets	Sell → Buy	$4 → $3.50
Sep-03-21	Downgrade	Truist	Buy → Hold	$4
Sep-03-21	Downgrade	Ladenburg Thalmann	Buy → Neutral
Sep-03-21	Downgrade	Chardan Capital Markets	Buy → Sell	$105 → $4
Sep-03-21	Downgrade	B. Riley Securities	Buy → Neutral	$3
May-14-21	Initiated	B. Riley Securities	Buy	$73
Mar-26-21	Initiated	Citigroup	Buy	$75
Aug-28-20	Upgrade	Chardan Capital Markets	Neutral → Buy	$45
Aug-25-20	Initiated	Truist	Buy	$70

Show Previous Ratings

Aug-12-26 03:41AM	Are SUNS, VREX, CHMI, FBRX Obtaining Fair Deals for their Shareholders? (PR Newswire)
Aug-06-26 03:48PM	Are MKTX, SMTI, FBRX, LXFR Obtaining Fair Deals for their Shareholders? (PR Newswire)
Aug-04-26 04:39PM	Are FBRX, LXFR, HUN, OLN Obtaining Fair Deals for their Shareholders? (PR Newswire)
Jul-28-26 05:35AM	Argenx signs agreement to buy Forte Biosciences for $2.2bn (Pharmaceutical Technology)
Jul-27-26 09:57PM	Why Did AAPL, FBRX, RTX Stocks Surge To 52-Week Highs Today? (Stocktwits) +39.65%
07:38PM	Loading…
07:38PM	Are FBRX, ACA, BGMS Obtaining Fair Deals for their Shareholders? (PR Newswire)
12:23PM	Forte Biosciences shares surge after argenx agrees to acquire company for $2.2B (Proactive)
08:28AM	Dow Jones still green but Nasdaq slips to start 'massive week' as oil tumbles (Proactive)
07:46AM	Argenx to acquire Forte in $2.2B deal for differentiated immune drug (BioPharma Dive)
07:12AM	FBRX Stock On Track For Highest Levels In Over 4.5 Years As ArgenX Scoops Up Autoimmune Drug Maker (Stocktwits)
06:47AM	Forte Biosciences shares jump after $2.2 billion takeover agreement with argenx (InvestorsHub)
06:46AM	Argenx agrees $2.2 billion acquisition of Forte Biosciences to strengthen autoimmune drug pipeline (InvestorsHub)
01:29AM	Argenx to Buy Forte Biosciences for $2.2 Billion (The Wall Street Journal)
01:07AM	argenx to Acquire Forte Biosciences, Inc., Adding First-in-Class Anti-CD122 Antibody, FB102, to Its Immunology Pipeline (Business Wire)
Jul-10-26 12:14PM	TRAX Stock Hits All-Time High What's Driving The Super Rally? (Stocktwits) +19.67%
01:26PM	Loading…
Jul-09-26 01:26PM	Forte Biosciences shares surge after positive phase 1b vitiligo results (Proactive) +78.33%
01:06PM	FBRX Stock On Track For Biggest Single-Day Gains In 20 Months Whats Behind The Super Rally? (Stocktwits)
10:09AM	Forte Biosciences Shares Climb After Positive Phase 1b Vitiligo Trial Results (FBRX) (InvestorsHub)
09:02AM	Enovix, Forte Biosciences rally premarket; PepsiCo slips (Investing.com)
May-11-26 04:01PM	Forte Biosciences, Inc. Reports Inducement Grant Under Nasdaq Listing Rules (Business Wire) +8.24% -6.58%
09:01AM	Forte Biosciences, Inc. Announces First Quarter 2026 Results and Provides Update (Business Wire)
Apr-08-26 09:30PM	Forte Biosciences Announces Pricing of $150 Million Public Offering (Business Wire) +29.04%
04:02PM	Forte Biosciences Announces Proposed Public Offering (Business Wire)
Mar-31-26 04:01PM	Forte Biosciences, Inc. Announces 2025 Results and Provides Update (Business Wire)
Mar-17-26 04:01PM	Forte Biosciences, Inc. Reports Inducement Grants Under Nasdaq Listing Rules (Business Wire) -6.01%
Mar-04-26 04:01PM	Forte Biosciences, Inc. Reports Inducement Grants Under NASDAQ Listing Rules (Business Wire)
Feb-25-26 12:00PM	Forte Biosciences (FBRX) Upgraded to Buy: Here's What You Should Know (Zacks)
Feb-09-26 04:01PM	Forte Biosciences, Inc. to Present at Upcoming Investor Meetings (Business Wire) +8.05%
Dec-22-25 04:01PM	Forte Biosciences, Inc. Reports Inducement Grant Under Nasdaq Listing Rules (Business Wire) -9.15%
Nov-24-25 04:01PM	Forte Biosciences, Inc. Reports Inducement Grant Under Nasdaq Listing Rules (Business Wire)
09:00AM	Loading…
Nov-14-25 09:00AM	Forte Biosciences, Inc. Announces Third Quarter 2025 Results and Provides Update (Business Wire)
Nov-03-25 04:01PM	Forte Biosciences, Inc. to Present at Upcoming Healthcare Conferences (Business Wire) -8.96% -7.39%
Oct-03-25 04:01PM	Forte Biosciences, Inc. Reports Inducement Grants Under Nasdaq Listing Rules (Business Wire) +15.25% -6.84%
Sep-15-25 09:00AM	Forte Biosciences, Inc. Announces Presentation of FB102 Celiac Disease Trial at Tampere Celiac Disease Symposium (Business Wire) +8.71%
Aug-14-25 04:01PM	Forte Biosciences, Inc. Announces Results and Provides Update (Business Wire) +6.93%
Jun-25-25 12:28AM	Forte Biosciences Announces Pricing of $75 Million Public Offering (Business Wire) -25.26%
Jun-24-25 04:01PM	Forte Biosciences Announces Proposed Public Offering (Business Wire) +11.05%
01:06PM	Forte Biosciences announces data from trial in celiac disease for FB102 (TipRanks)
Jun-23-25 07:18AM	Forte Biosciences Announces Positive Data in FB102 Celiac Disease Phase 1B Study (Business Wire) -12.96%
May-15-25 04:01PM	Forte Biosciences, Inc. Announces Results and Provides Update (Business Wire)
Apr-03-25 12:00PM	All You Need to Know About Forte Biosciences (FBRX) Rating Upgrade to Buy (Zacks) -10.48%
Mar-31-25 09:00AM	Forte Biosciences, Inc. Announces Results and Provides Clinical Update (Business Wire) -5.37%
Feb-03-25 09:00AM	Forte Biosciences, Inc. to Present at Upcoming Investor Meetings (Business Wire) -5.79%
Nov-25-24 09:00AM	Forte Biosciences to Host RandD Day December 3, 2024 (Business Wire)
09:00AM	Forte Biosciences to Host R&D Day December 3, 2024 (Business Wire)
Nov-20-24 09:00AM	Forte Biosciences, Inc. Announces Oversubscribed $53 Million Private Placement From Leading Healthcare Institutional Investors to Advance FB102 Across Autoimmune Indications (Business Wire) +128.69%
Nov-14-24 04:01PM	Forte Biosciences, Inc. Announces Third Quarter 2024 Results and Provides Business Update (Business Wire)
Aug-26-24 11:51AM	Upcoming Stock Splits This Week (August 26 to August 30) Stay Invested (TipRanks) +6.44%
Aug-14-24 09:54PM	FBRX Stock Earnings: Forte Biosciences Misses EPS for Q2 2024 (InvestorPlace) -7.80% -20.51%
04:01PM	Forte Biosciences, Inc. Announces Second Quarter 2024 Results and Provides Business Update (Business Wire)
Jul-15-24 10:26AM	Is Forte Biosciences, Inc. (FBRX) One of the Best Penny Stocks to Buy Now Under $1? (Insider Monkey)
09:35AM	10 Best Penny Stocks to Buy Under $1 (Insider Monkey)
May-17-24 04:05PM	Forte Biosciences, Inc. Reports Inducement Grants Under Nasdaq Listing Rules (Business Wire)
May-13-24 09:54PM	FBRX Stock Earnings: Forte Biosciences Reported Results for Q1 2024 (InvestorPlace)
04:05PM	Forte Biosciences, Inc. Announces First Quarter 2024 Results and Provides Business Update (Business Wire)
Mar-25-24 12:00PM	What Makes Forte Biosciences (FBRX) a New Buy Stock (Zacks)
Mar-19-24 06:53AM	FBRX Stock Earnings: Forte Biosciences Reported Results for Q4 2023 (InvestorPlace)
Mar-18-24 04:05PM	Forte Biosciences, Inc. Announces 2023 Results and Provides Business Update (Business Wire)
Dec-04-23 07:21AM	10 Best Debt Free Penny Stocks To Buy Now (Insider Monkey)
Dec-01-23 04:01PM	Forte Biosciences, Inc. Reports Inducement Grant Under Nasdaq Listing Rules (Business Wire) +5.06%
Nov-13-23 04:01PM	Forte Biosciences, Inc. Announces Third Quarter 2023 Results and Provides Business Update (Business Wire) -9.47%
Sep-14-23 10:50AM	ISS and Glass Lewis Recommend Forte Biosciences Stockholders Vote FOR Boardroom Change at the Companys Upcoming Annual Meeting (Business Wire)
Sep-06-23 03:15PM	Concerned Stockholders of Forte Biosciences and Its Independent Director Candidates Share Key Facts that Reinforce the Need for Urgent Change in the Companys Boardroom (Business Wire)
Aug-25-23 08:00AM	Concerned Stockholders of Forte Biosciences File Definitive Proxy Statement and Send Letter to Stockholders (Business Wire)
Aug-14-23 04:01PM	Forte Biosciences, Inc. Announces Second Quarter 2023 Results and Provides Business Update (Business Wire) -6.93%
Aug-01-23 04:01PM	Forte Biosciences, Inc. Announces $25 Million Financing and R&D Update for FB-102 (Business Wire) -5.65%
Jun-20-23 08:00AM	Jasper Therapeutics Appoints Scott Brun, M.D., to its Board of Directors (GlobeNewswire)
May-19-23 04:01PM	Forte Biosciences, Inc. Reports Inducement Grant Under Nasdaq Listing Rules (Business Wire)
May-15-23 04:01PM	Forte Biosciences, Inc. Announces First Quarter 2023 Results and Provides Business Update (Business Wire)
Mar-31-23 04:05PM	Forte Biosciences, Inc. Announces Full Year 2022 Results and Provides Business Update (Business Wire)
Jan-12-23 04:05PM	Mr. David Gryska Appointed to Forte Biosciences Board of Directors (Business Wire)
Nov-14-22 04:01PM	Forte Biosciences, Inc. Announces Third Quarter 2022 Results and Provides Business Update (Business Wire)
04:01PM	Dr. Scott Brun, M.D. Appointed to Forte Biosciences Board of Directors (Business Wire)
Aug-17-22 08:00AM	Camac Partners Condemns Forte Biosciences Seemingly Defensive and Unjustifiable Capital Raise (Business Wire)
Aug-15-22 04:05PM	Forte Biosciences, Inc. Announces Second Quarter 2022 Results and Provides Business Update (Business Wire)
Jul-08-22 07:16AM	We're Keeping An Eye On Forte Biosciences' (NASDAQ:FBRX) Cash Burn Rate (Simply Wall St.) +6.99%
Jun-07-22 09:00AM	Forte Biosciences, Inc. Reports Inducement Grants Under Nasdaq Listing Rules (Business Wire) +10.17%
09:00AM	Forte Biosciences, Inc. Announces the Appointment of Dr. Hubert Chen, MD as Chief Scientific Officer and President (Business Wire)
May-16-22 09:00AM	Forte Biosciences, Inc. Announces First Quarter 2022 Results and Provides Business Update (Business Wire) -8.90%
Dec-15-21 05:55AM	Here's Why We're Watching Forte Biosciences' (NASDAQ:FBRX) Cash Burn Situation (Simply Wall St.) -5.16%
Sep-09-21 06:15PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Forte Biosciences, Inc. FBRX (GlobeNewswire)
Sep-08-21 08:51AM	ONGOING INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Forte Biosciences, Inc. and Encourages Investors with Losses to Contact the Firm (Business Wire)
Sep-07-21 09:40PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Forte Biosciences, Inc. FBRX (ACCESSWIRE) -17.19%
Sep-06-21 12:42PM	INVESTIGATION REMINDER: The Schall Law Firm Announces It Is Investigating Claims Against Forte Biosciences, Inc. and Encourages Investors with Losses to Contact the Firm (Newsfile)
Sep-03-21 07:42PM	INVESTIGATION REMINDER: The Schall Law Firm Announces It Is Investigating Claims Against Forte Biosciences, Inc. and Encourages Investors With Losses to Contact the Firm (Business Wire) -82.30% -17.19%
02:14PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Forte Biosciences, Inc. - FBRX (PR Newswire)
11:15AM	Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of Forte Biosciences, Inc. (FBRX) Investigation (ACCESSWIRE)
Sep-02-21 04:05PM	Clinical Trial of FB-401 For the Treatment of Atopic Dermatitis Fails to Meet Statistical Significance (Business Wire)
Aug-16-21 04:05PM	Forte Biosciences, Inc. to Review the Second Quarter 2021 Results and Expects to Announce Topline Data From Phase 2 Clinical Trial of FB-401 for the Treatment of Atopic Dermatitis on Sept. 7 (Business Wire) -6.11% +12.23%
Aug-02-21 04:01PM	Forte Biosciences, Inc. Reports Inducement Grants Under Nasdaq Listing Rules (Business Wire)
Jul-12-21 04:01PM	Forte Biosciences, Inc. Reports Inducement Grants Under Nasdaq Listing Rules (Business Wire) -7.72%
Jul-07-21 10:02AM	Implied Volatility Surging for Forte Biosciences (FBRX) Stock Options (Zacks) -7.57%
Jul-01-21 04:01PM	Forte Biosciences, Inc. Reports Inducement Grants Under Nasdaq Listing Rules (Business Wire)
May-14-21 03:06AM	Read This Before Selling Forte Biosciences, Inc. (NASDAQ:FBRX) Shares (Simply Wall St.)
May-10-21 04:05PM	Forte Biosciences, Inc. Announces First Quarter 2021 Results and Provides a General Business Update (Business Wire)
02:30PM	Forte Biosciences Inc to Host Earnings Call (ACCESSWIRE)
May-03-21 04:30PM	Forte Biosciences, Inc. to Announce First Quarter 2021 Results and Provide a General Business Update (Business Wire) -5.36%
Mar-25-21 08:42AM	Forte Posts Lower-Than-Feared Quarterly Loss; Shares Drop 9.5% (SmarterAnalyst) +15.63%
Mar-24-21 08:00AM	Forte Biosciences, Inc. Announces 4Q and Full Year 2020 Results and Provides a General Business Update (Business Wire) -9.52%
06:30AM	Forte Biosciences Inc to Host Earnings Call (ACCESSWIRE)

Forte Biosciences, Inc. is a biopharmaceutical company, which engages in the provision of dermatology products and services. Its lead product includes FB-401, which is a live biotherapeutic for the treatment of inflammatory skin disease, including pediatric and adult patients with atopic dermatitis. The company was founded by Paul A. Wagner on May 3, 2017 and is headquartered in Dallas, TX.

CEODr. Paul A. Wagner Ph.D.

Chief Financial OfficerMr. Antony A. Riley CPA

Senior Medical Clinician & DirectorDr. Barbara K. Finck M.D.

Chief Operating OfficerMr. Christopher Roenfeldt

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Wagner Paul A.	SEE REMARKS	Jan 01 '26	Option Exercise	0.00	1,250	0	83,342	Jan 02 04:07 PM
Riley Antony A	CHIEF FINANCIAL OFFICER	Jan 01 '26	Option Exercise	0.00	375	0	41,895	Jan 02 04:04 PM
Riley Antony A	CHIEF FINANCIAL OFFICER	Dec 30 '25	Buy	26.33	9,680	254,833	41,520	Jan 02 04:04 PM
Riley Antony A	CHIEF FINANCIAL OFFICER	Oct 01 '25	Option Exercise	0.00	375	0	31,974	Oct 02 04:10 PM
Wagner Paul A.	SEE REMARKS	Oct 01 '25	Option Exercise	0.00	1,250	0	82,190	Oct 02 04:09 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

FBRX

Forte Biosciences Inc

Upgrade your Finviz experience